PT Bundamedik Tbk Statistics

Total Valuation

PT Bundamedik Tbk has a market cap or net worth of IDR 2.44 trillion. The enterprise value is 3.30 trillion.

Market Cap	2.44T
Enterprise Value	3.30T

Important Dates

The next estimated earnings date is Friday, November 1, 2024.

Earnings Date	Nov 1, 2024
Ex-Dividend Date	Jun 10, 2024

Share Statistics

PT Bundamedik Tbk has 8.60 billion shares outstanding.

Shares Outstanding	8.60B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	16.27%
Owned by Institutions (%)	n/a
Float	1.85B

Valuation Ratios

The trailing PE ratio is 172.50 and the forward PE ratio is 53.58.

PE Ratio	172.50
Forward PE	53.58
PS Ratio	1.58
PB Ratio	1.53
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.75, with an EV/FCF ratio of -15.06.

EV / Earnings	232.70
EV / Sales	2.13
EV / EBITDA	13.75
EV / EBIT	30.88
EV / FCF	-15.06

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.68.

Current Ratio	1.51
Quick Ratio	1.30
Debt / Equity	0.68
Debt / EBITDA	5.13
Debt / FCF	-5.62
Interest Coverage	1.82

Financial Efficiency

Return on equity (ROE) is 1.59% and return on invested capital (ROIC) is 2.30%.

Return on Equity (ROE)	1.59%
Return on Assets (ROA)	2.19%
Return on Capital (ROIC)	2.30%
Revenue Per Employee	1.08B
Profits Per Employee	9.88M
Employee Count	1,434
Asset Turnover	0.51
Inventory Turnover	20.94

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.00% in the last 52 weeks. The beta is -0.22, so PT Bundamedik Tbk's price volatility has been lower than the market average.

Beta (5Y)	-0.22
52-Week Price Change	-28.00%
50-Day Moving Average	292.28
200-Day Moving Average	309.16
Relative Strength Index (RSI)	50.44
Average Volume (20 Days)	2,269,315

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PT Bundamedik Tbk had revenue of IDR 1.55 trillion and earned 14.16 billion in profits. Earnings per share was 1.65.

Revenue	1.55T
Gross Profit	709.58B
Operating Income	106.73B
Pretax Income	56.25B
Net Income	14.16B
EBITDA	208.61B
EBIT	106.73B
Earnings Per Share (EPS)	1.65

Full Income Statement

Balance Sheet

The company has 588.20 billion in cash and 1.23 trillion in debt, giving a net cash position of -641.81 billion or -74.60 per share.

Cash & Cash Equivalents	588.20B
Total Debt	1.23T
Net Cash	-641.81B
Net Cash Per Share	-74.60
Equity (Book Value)	1.81T
Book Value Per Share	185.57
Working Capital	294.06B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 52.57 billion and capital expenditures -271.39 billion, giving a free cash flow of -218.82 billion.

Operating Cash Flow	52.57B
Capital Expenditures	-271.39B
Free Cash Flow	-218.82B
FCF Per Share	-25.43

Full Cash Flow Statement

Margins

Gross margin is 45.75%, with operating and profit margins of 6.88% and 0.91%.

Gross Margin	45.75%
Operating Margin	6.88%
Pretax Margin	3.63%
Profit Margin	0.91%
EBITDA Margin	13.45%
EBIT Margin	6.88%
FCF Margin	-14.11%

Dividends & Yields

This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 0.53%.

Dividend Per Share	1.50
Dividend Yield	0.53%
Dividend Growth (YoY)	-62.67%
Years of Dividend Growth	n/a
Payout Ratio	48.27%
Buyback Yield	n/a
Shareholder Yield	0.53%
Earnings Yield	0.58%
FCF Yield	-8.96%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PT Bundamedik Tbk has an Altman Z-Score of 2.15. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.15
Piotroski F-Score	n/a